<code id='5644CB9BE6'></code><style id='5644CB9BE6'></style>
    • <acronym id='5644CB9BE6'></acronym>
      <center id='5644CB9BE6'><center id='5644CB9BE6'><tfoot id='5644CB9BE6'></tfoot></center><abbr id='5644CB9BE6'><dir id='5644CB9BE6'><tfoot id='5644CB9BE6'></tfoot><noframes id='5644CB9BE6'>

    • <optgroup id='5644CB9BE6'><strike id='5644CB9BE6'><sup id='5644CB9BE6'></sup></strike><code id='5644CB9BE6'></code></optgroup>
        1. <b id='5644CB9BE6'><label id='5644CB9BE6'><select id='5644CB9BE6'><dt id='5644CB9BE6'><span id='5644CB9BE6'></span></dt></select></label></b><u id='5644CB9BE6'></u>
          <i id='5644CB9BE6'><strike id='5644CB9BE6'><tt id='5644CB9BE6'><pre id='5644CB9BE6'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:643
          Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

          Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

          The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

          advertisement

          But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          What does generative AI mean for health care? We asked experts
          What does generative AI mean for health care? We asked experts

          MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

          read more
          FDA panel endorses Alnylam’s heart drug — after picking it apart
          FDA panel endorses Alnylam’s heart drug — after picking it apart

          KristofferTripplaar/SipaUSA/APAgroupofadviserstotheFoodandDrugAdministrationvotedinfavorofAlnylamPha

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Ionis has late

          AdobeIonisPharmaceuticals,aCaliforniabiotechthathasspearheadedthedevelopmentofRNA-targetingmedicines